PT  - JOURNAL ARTICLE
AU  - TOMOHARU YOSHIZUMI
AU  - NORIFUMI HARIMOTO
AU  - SHINJI ITOH
AU  - HIROHISA OKABE
AU  - KOICHI KIMURA
AU  - HIDEAKI UCHIYAMA
AU  - TORU IKEGAMI
AU  - TETSUO IKEDA
AU  - YOSHIHIKO MAEHARA
TI  - Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era
DP  - 2016 Jan 01
TA  - Anticancer Research
PG  - 439--445
VI  - 36
IP  - 1
4099  - http://ar.iiarjournals.org/content/36/1/439.short
4100  - http://ar.iiarjournals.org/content/36/1/439.full
SO  - Anticancer Res2016 Jan 01; 36
AB  - Background: The aim of the present study was to clarify the outcome of living donor liver transplantation (LDLT) in patients with hepatocellular carcinoma (HCC) within Milan criteria. Patients and Methods: The study comprised of 197 adult patients. One hundred twenty-nine patients were within Milan criteria. The overall and recurrence-free survival rates after the LDLT were calculated. Results: The 1-, 5- and 10-year overall survival rates were 94.5%, 89.9% and 88.6%, respectively. The 1-, 5- and 10-year recurrence-free survival rates were 100%, 97.0% and 94.0%, respectively. Four patients had HCC recurrence. The mean neutrophil to lymphocyte ratio (NLR) (6.75 vs. 2.75, p=0.002) or alpha-fetoprotein (AFP) (3,239 vs. 197, p<0.001) of these four recipients was significantly higher compared to that of 125 recipients without HCC recurrence. Conclusion: The outcome of LDLT for patients with HCC within Milan criteria was outstanding. Careful follow-up after LDLT is necessary for patients with high NLR or AFP.